Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Coronavirus

During May, nations in the European epicenter of the COVID-19 pandemic began to loosen the lockdown measures they imposed in mid-to-late March. Economic pressures largely drove national decisions to reopen business and industry – but without either full justification on health grounds or the full confidence of the population.

German health minister Jens Spahn on several occasions warned publicly that the pandemic was far from over, and its effects...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

 

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

COVID To GLP-1: Catalent Plants Ride With Novo To Next Public Health Crisis

 
• By 

A complex transformation is underway as client proposes to acquire CDMO facilities that vaccinated the world against the COVID-19 pandemic for pivot to the obesity epidemic.

Outlook 2024: Biopharma Embraces New Markets And New Tech

 

New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024? 

After All The Layoffs, Is Biopharma’s Headcount Still Growing?

 

While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.

More from In Vivo